After eating, you ask whether you would feel better with two more bites, a sip of water, or a walk
Currently available GLP-1 receptor agonists in the UK include: Exenatide (short-acting and extended-release formulations) - licensed for type 2 diabetes Liraglutide (once-daily injection) - licensed for type 2 diabetes (Victoza) and separately for weight management (Saxenda 3mg) Dulaglutide (once-weekly injection) - licensed for type 2 diabetes, including cardiovascular risk reduction in those with established cardiovascular disease or multiple risk factors Semaglutide (once-weekly injection and oral formulation) - licensed for type 2 diabetes (Ozempic, Rybelsus) and separately for weight management (Wegovy 2.4mg) A related but distinct medication is tirzepatide (once-weekly injection), which is a dual GIP/GLP-1 receptor agonist licensed for type 2 diabetes management
Apr 3, 2026 You have read the articles
The primary endpoint is incident hepatic decompensation defined as occurrence of any one of the following: variceal hemorrhage, ascites, hepatic encephalopathy, or hepatocellular carcinoma (HCC)
And while consumer data shows the demand is real, realizing that upside may be difficult
